Gallagher J C, Riggs B L, Eisman J, Hamstra A, Arnaud S B, DeLuca H F
J Clin Invest. 1979 Sep;64(3):729-36. doi: 10.1172/JCI109516.
Intestinal calcium absorption assessed by a double-isotope method, decreased significantly with aging in 94 normal subjects (r = -0.22, P < 0.025). In 52 untreated patients with postmenopausal osteoporosis, calcium absorption was significantly lower than normal when either age or habitual calcium intake was used as a covariable (P < 0.001). Serum 25-hydroxyvitamin D (25-OH-D) and 1,25-dihydroxyvitamin D (1,25(OH)(2)D) were measured in 44 normal subjects and 27 osteoporotic patients. For all normals, calcium absorption and serum 1,25(OH)(2)D were positively correlated (r = 0.50, P < 0.001). In nonelderly normal subjects (ages 30-65 yr), dietary calcium intake correlated inversely with both calcium absorption (r = -0.39, P < 0.01) and with serum 1,25(OH)(2)D (r = -0.50, P < 0.01). Both osteoporotic patients and elderly normal subjects (ages 65-90 yr) differed from nonelderly normals in that these correlations were not present. In addition although serum 25-OH-D was normal, serum 1,25(OH)(2)D was significantly decreased in both osteoporotic patients and elderly normals (P < 0.001). In osteoporotic patients, calcium absorption increased significantly (P < 0.001) after 7 d administration of a small dose (0.4 mug/d) of synthetic 1,25(OH)(2)D(3). In osteoporotics mean serum immunoreactive parathyroid hormone was either normal (COOH-terminal assay) or low (NH(2)-terminal assay) relative to age-matched controls, and mean serum phosphate was increased. The data suggest that inadequate metabolism of 25-OH-D to 1,25(OH)(2)D contributes significantly to decreased calcium absorption and adaptation in both osteoporotics and elderly normal subjects. In patients with osteoporosis this abnormality could result from a decrease in factors that normally stimulate 1,25(OH)(2)D production, such as the decreased parathyroid hormone secretion and increased serum phosphate demonstrated in this group. In elderly subjects a primary abnormality in metabolism of 25-OH-D to 1,25(OH)(2)D, analagous to that seen in aging rats, cannot be excluded.
采用双同位素法评估肠道钙吸收,94名正常受试者的肠道钙吸收随年龄增长显著下降(r = -0.22,P < 0.025)。在52名未经治疗的绝经后骨质疏松症患者中,以年龄或习惯性钙摄入量作为协变量时,钙吸收显著低于正常水平(P < 0.001)。对44名正常受试者和27名骨质疏松症患者测定了血清25-羟维生素D(25-OH-D)和1,25-二羟维生素D(1,25(OH)₂D)。对于所有正常受试者,钙吸收与血清1,25(OH)₂D呈正相关(r = 0.50,P < 0.001)。在非老年正常受试者(30 - 65岁)中,膳食钙摄入量与钙吸收(r = -0.39,P < 0.01)以及血清1,25(OH)₂D(r = -0.50,P < 0.01)均呈负相关。骨质疏松症患者和老年正常受试者(65 - 90岁)与非老年正常受试者不同,不存在这些相关性。此外,尽管血清25-OH-D正常,但骨质疏松症患者和老年正常受试者的血清1,25(OH)₂D均显著降低(P < 0.001)。在骨质疏松症患者中,给予小剂量(0.4μg/d)合成1,25(OH)₂D₃ 7天后,钙吸收显著增加(P < 0.001)。相对于年龄匹配的对照组,骨质疏松症患者的血清免疫反应性甲状旁腺激素平均水平正常(羧基末端测定)或较低(氨基末端测定),且血清磷酸盐平均水平升高。数据表明,2,5-OH-D向1,25(OH)₂D的代谢不足在很大程度上导致了骨质疏松症患者和老年正常受试者钙吸收减少及适应性降低。在骨质疏松症患者中,这种异常可能是由于正常刺激1,25(OH)₂D产生的因素减少所致,如该组患者甲状旁腺激素分泌减少和血清磷酸盐升高。在老年受试者中,不能排除25-OH-D向1,25(OH)₂D代谢的原发性异常,这与在衰老大鼠中观察到的情况类似。